1 Department of Basic Medical Science for Nursing, Department of Primary Education, Yasuda Women's University, Hiroshima, Japan.
2 Shimane University School of Medicine, Izumo, Shimane, Japan.
Am J Chin Med. 2017;45(8):1597-1611. doi: 10.1142/S0192415X17500860. Epub 2017 Nov 9.
The high incidence of tuberculosis (TB) in developing countries, the resurgence of TB in industrialized countries, and the worldwide increase in the prevalence of Mycobacterium avium complex infections have prompted the quest for new antimycobacterial drugs. However, the development of such chemotherapeutics is currently making very slow progress. It therefore appears that devising improved administration protocols for clinical treatment against intractable mycobacteriosis using existing chemotherapeutics is more practical than awaiting the development of novel antimycobacterial drugs. The modulation of host immune responses using immunoadjunctive agents may increase the efficacy of antimicrobial treatment against mycobacteriosis. Particularly, the mild and long-term up-regulation of host immune reactions against mycobacterial pathogens using Chinese herbal medicines (CHMs) may be beneficial for immunoadjunctive therapy. This review focuses on the current status and future prospects regarding the development of CHMs that can be useful for the clinical control of intractable mycobacterial infections.
发展中国家结核病（TB）发病率高，工业化国家结核病死灰复燃，以及全世界范围内鸟分枝杆菌复合体感染的流行率增加，促使人们寻求新的抗分枝杆菌药物。然而，此类化学疗法的开发目前进展非常缓慢。因此，似乎利用现有的化学疗法设计针对难治性分枝杆菌病的临床治疗的改进管理方案比等待新型抗分枝杆菌药物的开发更为实际。使用免疫佐剂调节宿主免疫反应可能会提高针对分枝杆菌病的抗菌治疗的疗效。特别是，使用中草药（CHM）温和且长期地上调宿主对分枝杆菌病原体的免疫反应可能对免疫佐剂治疗有益。本综述重点介绍了在开发可用于临床控制难治性分枝杆菌感染的 CHM 方面的现状和未来前景。
